Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Characterizing the Theranostic Potential of DLL3-targeting Agents in High-grade Neuroendocrine Carcinomas of the Lung and Prostate

NCT06941480 is registered in ClinicalTrials.gov with Memorial Sloan Kettering Cancer Center as lead sponsor.

NCT NCT06941480
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06941480 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Characterizing the Theranostic Potential of DLL3-targeting Agents in High-grade Neuroendocrine Carcinomas of the Lung and Prostate
Lead sponsor
Memorial Sloan Kettering Cancer Center
Phase
Phase 1
Overall status
Not yet recruiting
Start date
September 30, 2026
Completion date
May 31, 2030
Enrollment
12 (estimated)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

neuroendocrine carcinoma, neuroendocrine carcinoma of lung, neuroendocrine carcinoma of prostate, neuroendocrine tumor of the lung